Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fampridine for motor and non-motor symptoms of Parkinson's disease
IRCT20230905059361N1Phase 3Completed
- Sponsor
- Shahrekord University of Medical Sciences
- Start
- Sep 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of dalfampridine in Parkinson's disease (PD) (2 arms), sponsored by Shahrekord University of Medical Sciences. Primary endpoints: Tremor condition, Bradykinesia situation and 9 more. Started Sep 2023; status: completed.
02
Drugs
dalfampridine
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on IRCT20230905059361N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20230905059361N1.